AlphaMadera's AlphaVal page computes Kimberly-Clark Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag KMB as undervalued, fairly valued, or overvalued.

What is Kimberly-Clark Corporation's fair value?

Fair value for KMB is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value KMB?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from KMB's most recent reported fundamentals.

KMB - Kimberly-Clark Corporation

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $103.75 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Fair Value Mild

Trading 4.8% below fair value

Current Price $99.14

Bear Case $85.77 13.5% downside ($85.77 - $99.14) / $99.14 = -13.5% $6.09 × 14x P/E

Fair Value $104.15 5.1% upside ($104.15 - $99.14) / $99.14 = 5.1% $6.09 × 17x P/E

Bull Case $122.53 23.6% upside ($122.53 - $99.14) / $99.14 = 23.6% $6.09 × 20x P/E

Adjust Assumptions

P/E Multiple

17.1x

Adjusted EPS

6.09$

Key Value Driver

Normalized P/E multiple (17x base case)

Implied Market Multiple 16.3x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $103.75 from 31 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $104.15 per share.

Warnings

⚠ The company pays out 84% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples